BIBLIOGRAPHY 
I. . Sznol, M., Mier, J.M., Sparano, J., Gaynor, E.R., Weiss, G.R., Margolin, K.A., Bar, M.H., 
Hawkins, M.J., Atkins, M.G., Dutcher, J.P., Fisher, R.I., Boldt, D.H., Doroshow, J.H., Louie, 
A.P., and Aronson, F.R.: A phase I study of interleukin-2 in combination with interferon-alfa 
2b. J. Biol. Resp. Mod. 9:529-537. 1990. 
2. Bar, M.H., Sznol, M., Atkins, M B., Ciobanu, N., Micetich, K.C., Boldt, D.H., Margolin, K.A., 
Aronson, F.R., Rayner, A. A., Hawkins, M.J., Mier, J.W., Paietta, E. t Fisher, R.I., Weiss, G.R., 
and Doroshow, J.H.: Metastatic malignant melanoma treated with combined bolus and 
continuous infusion interleukin-2 and lymphokine-activated killer cells. J. Clin. Oncol. 8:1138- 
1147, 1990. 
3. Sznol, M. and Urba, W.J.: Adoptive cellular therapy. In Pinedo, H.M., Longo, D.L., and 
Chabner, B.A.: Cancer Chemotherapy and Biological Response Modifiers: Annual 12 . 
Amsterdam, Elsevier Science Publishers B.V., 1991, pp. 213-230. 
4. Sznol, M. and Urba, W.J.: Adoptive cellular therapy. In Pinedo, H.M., Longo, D.L., and 
Chabner, B.A.: Cancer Chemotherapy and Biological Response Modifiers :Annual 13 . 
Amsterdam, Elsevier Science Publishers B.V., 1992, pp 191-204. 
5. Sznol, M. and Ohnuma, T.: Hepatotoxic effects of cancer and its treatment. In Holland, J.F., 
Frei, E. Ill, Bast, R. Jr., Kufe, D., Morton, D., Weichselbaum, R., (Eds): Cancer Medicine. 3rd 
Edition , Lea and Febiger, Philadelphia, PA, 1992, pp. 2358-2369. 
6. Sznol, M., Clark, J.W., Smith II, J.W., Steis, R.G., Urba, W.J., Rubinstein, L.V., VanderMolen, 
L. A., Janik, J., Sharfman, W.H., Fenton, R.G., Creekmore, S.P., Kremers, P., Conlon, K., 
Hursey, J., Beveridge, J., and Longo, D.L.: Pilot study of interleukin-2 and lympholine- 
activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced 
with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J. Natl. 
Cancer Inst. , 84: 929-937, 1992. 
7. Sznol, M. and Hawkins, M.J.: lnterleukin-2 in malignancies other than melanoma and renal 
cell carcinoma. In Atkins, M B. and Mier, J.W. (Eds): Therapeutic Applications of IL-2 , Marcel 
Dekker, Inc., New York, 1993, pp. 177-188. 
8. Sznol, M., Thurn, A., Aronson, F.R.: IL-2 in combination with other biologic agents. In Atkins, 
M. B., and Mier, J.W. (Eds.): Therapeutic Applications of IL-2 . Marcel Dekker, Inc., New York, 
1993, pp. 233-275. 
9. Sznol M, Urba WJ. Adoptive cellular therapy. In: Pinedo HM, Longo DL, Chabner BA (Eds): 
Cancer Chemotherapy and Biological Response Modifiers: Annual 14 . Elsevier Science 
Publishers B.V., Amsterdam, 1993, in press. 
10. Sznol M, Steis RG. Smith II JW, Janik JE, Sharfman WH, Urba WJ, Fenton RG, Creekmore 
SP, Beveridge J, Longo DL. Intensive therapy with cisplatin, lnterleukin-2 and interferon- 
alpha-2a in patients with metastatic melanoma. Online J Curr Clin Trials 1992; July 1:1992 
(Doc No 9). 
II. Atkins MB, Sparano J, Fisher Rl, Weiss GR, Margolin KA, Fink Kl, Rubinstein L, Louie A, Mier 
JW, Gucalp R, Sosman JA, Boldt DH, Doroshow JH, Aronson FR, Sznol M. Randomized 
phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in 
advanced renal cell carcinoma. J Clin Oncol 11: 661-70, 1993. 
12. Sznol M, Longo DL. Chemotherapy drug interactions with biological agents. Sem Oncol 20: 
80-93, 1993. 
13. Sznol M, Parkinson DR. Clinical Applications of lnterleukin-2. Oncol , in press. 
[748] 
Recombinant DNA Research, Volume 18 
